Sugarbaker P H, Zhu B W, Sese G B, Shmookler B
Cancer Institute, Washington Hospital Center, Washington, D.C. 20010.
Dis Colon Rectum. 1993 Apr;36(4):323-9. doi: 10.1007/BF02053933.
Sixty-nine patients presenting over a 10-year period with peritoneal carcinomatosis from appendiceal cancer were treated with cytoreductive surgery combined with intraperitoneal chemotherapy. The three-year survival is 89.5 percent in patients (38/69) with pseudomyxoma peritonei, 34.5 percent in patients (25/69) with cystadenocarcinoma, and 38.1 percent in patients (6/69) with adenocarcinoma (P < 0.01). In this study, a classification of residual disease following the cytoreductive surgery was used. The prognosis of the patients with minimal residual disease was better than that of those with moderate or gross disease, showing a 91.6 percent three-year survival compared with 47.8 percent and 20 percent, respectively (P < 0.01). The patients without lymphatic or hematogenous metastases had a better three-year survival than those with metastases (75.1 percent vs. 28.6 percent; P < 0.01). These findings suggest that peritoneal carcinomatosis from appendiceal cancer can be treated with long-term disease-free survival. The patients with low malignant potential cancer, complete cytoreduction, and no metastases showed the most effective disease control.
69例在10年期间因阑尾癌出现腹膜癌转移的患者接受了细胞减灭术联合腹腔内化疗。黏液性腹膜假瘤患者（38/69）的三年生存率为89.5%，囊腺癌患者（25/69）为34.5%，腺癌患者（6/69）为38.1%（P<0.01）。在本研究中，采用了细胞减灭术后残留病灶的分类方法。微小残留病灶患者的预后优于中度或肉眼可见病灶患者，三年生存率分别为91.6%、47.8%和20%（P<0.01）。无淋巴或血行转移的患者三年生存率高于有转移的患者（75.1%对28.6%；P<0.01）。这些发现表明，阑尾癌腹膜癌转移可以通过长期无病生存进行治疗。恶性潜能低、细胞减灭彻底且无转移的患者疾病控制效果最佳。
